The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player
With the biotech boom in the US in full swing, more money than ever is flowing into the industry — but that gusher hasn’t fully translated across the pond. Now, a Danish biotech with some big-name backers has scored a record-high early fundraising round. Is it a one-off or a sign of things to come?
Copenhagen-based ADCendo has bagged a $62 million Series A round — the largest ever of its kind for a Danish biotech — to advance its pipeline of antibody-drug conjugates targeting uPARAP, a collagen scavenger receptor on some tumor cells, the company said Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
